显色法与一步法检测诊断女性血友病A:全球方法映射与挑战评估——国际血栓与止血学会科学标准化委员会通讯
国际血栓与止血学会科学标准化委员会工作组通过全球调查研究血友病诊疗提供者对女性血友病A(WGwHA)的诊断方法。174名受访者中,35%的女性患者使用显色法(CSA)±一步法(OSA),低于男性患者的61%(P<.001);62%的提供者对WGwHA使用OSA;29%和33%的提供者未使用出血评估工具和基因检测诊断WGwHA。
要点
- 女性血友病A使用显色法±一步法的提供者比例(35%)低于男性(61%),P<.001。
- 62%的提供者对女性血友病A使用一步法,原因涉及检测相关因素。
- 29%和33%的提供者分别未使用出血评估工具和基因检测诊断女性血友病A。
核心结论
- 调查结果显示,诊断女性血友病A时显色法的使用频率低于男性血友病A,可能源于成本、可及性和保险覆盖等检测相关因素,也可能部分提供者未考虑女性血友病A的检测差异。
- 提高全球可及性并改善提供者对女性血友病A检测差异的考虑可增加两种检测的使用,改善检测和其他诊断工具(如出血评估工具评分)的使用将改善女性血友病A的有效诊断。
研究设计与样本
- 国际血栓与止血学会科学标准化委员会FVIII、FIX和罕见凝血障碍委员会及儿科与新生儿血栓与止血委员会召集工作组,编制Research Electronic Data Capture调查并分发给全球血友病诊疗提供者,采用描述性统计。
主要发现
- 174名受访者中95%为血友病诊疗提供者,包括34%成人血液科医生、58%儿科血液科医生、2%执业护士和0.5%护士;95%为女性血友病A和女性血友病A/B的提供者。
- 女性(WG)中使用显色法±一步法的提供者比例(35%)低于男性(MB,61%),P<.001。
- 62%的提供者对女性血友病A使用一步法,原因涉及多种检测相关因素。
- 29%的提供者未使用出血评估工具诊断女性血友病A,33%的提供者未使用基因检测诊断女性血友病A。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Assay discrepancies are well recognized in diagnosing men and boys with hemophilia A (MBwHA), but are not well studied in women and girls with hemophilia A (WGwHA). OBJECTIVES: To survey hemophilia providers to map global approaches/perspectives/challenges in diagnosing WGwHA with a chromogenic assay (CSA) vs one-stage assay (OSA) and other diagnostic tools to diagnose WGwHA compared with MBwHA. METHODS: The International Society on Thrombosis and Haemostasis Scientific and Standardization Committees on FVIII, FIX and Rare Coagulation Disorders and Pediatric and Neonatal Thrombosis and Haemostasis convened a working group, which compiled a Research Electronic Data Capture survey and disseminated it to global hemophilia providers. Descriptive statistics were applied to survey results. RESULTS: Of 174 respondents, 95% were hemophilia providers, comprising 34% adult hematologists, 58% pediatric hematologists, 2% nurse practitioners, and 0.5% nurses; 95% were providers for WGwHA and WGwHMB. The results showed that CSA with/without OSA is ordered by fewer providers in women and girls (WG, 35%) than in men and boys (MB, 61%; P < .001). OSA is ordered by more providers (62%) in WGwHA due to various assay-related reasons. Bleeding Assessment Tool and genetic testing were not used to diagnose WGwHA by 29% and 33%, respectively. CONCLUSION: Based on our survey results, CSA is ordered less frequently in diagnosing WGwHA compared with MBwHA, likely due to assay-related factors including cost, availability, and insurance coverage, and possibly due to some providers not considering assay discrepancies in WGwHA. Increasing global availability and improving provider consideration of assay discrepancies in WGwHA can increase use of both assays. Improved use of assays and other diagnostic tools, such as Bleeding Assessment Tool scores, will improve effective diagnoses of WGwHA.
引用
- Srivaths L, Larson J, Fijnvandraat K, et al. Chromogenic vs one-stage assay to diagnose women and girls with hemophilia A-mapping global approaches and assessing challenges: communication from the SSCs of the ISTH. J Thromb Haemost. 2025. PMID: 40374114. doi:10.1016/j.jtha.2025.05.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。